ABSTRACT This study synthesized and characterized amoxicillin‐functionalized Ag/AgCl nanoparticles (Amoxicillin@Ag/AgCl NPs) for biomedical applications. The nanoparticles were prepared via a coprecipitation method and functionalized with amoxicillin to enhance therapeutic potential. Characterization techniques (X‐ray diffraction XRD, Fourier‐transform infrared (FTIR), scanning electron microscopy SEM, and UV–Vis) confirmed successful functionalization and improved physicochemical properties. The crystallite size increased from 17.29 ± 3.44 to 20.47 ± 4.17 nm, while the bandgap widened from 2.33 to 2.40 eV, indicating enhanced electronic interactions. Antioxidant activity was significantly improved, with 2,2′‐azino‐bis(3‐ethylbenzothiazoline‐6‐sulfonic acid) (ABTS) radical scavenging reaching 97.87% and β‐carotene bleaching inhibition at 95.47% (175 μg/mL). The antibiofilm efficacy was notable, with inhibition rates of 90.24% for E. coli (250 μg/mL), 81.47% for S. typhimurium (175 μg/mL), and 87.68% for B. subtilis (250 μg/mL). In enzymatic inhibition studies, Amoxicillin@Ag/AgCl NPs showed neuroprotective potential, inhibiting acetylcholinesterase (AChE) (93.74% at 160 μg/mL) and butyrylcholinesterase (BChE) (97.41% at 80 μg/mL), highlighting their potential in Alzheimer's treatment. Additionally, they exhibited anti‐inflammatory effects, inhibiting lipoxygenase (LOX) by 90.47% (120 μg/mL). To the best of our knowledge, this is the first report on the synthesis of Amoxicillin@Ag/AgCl NPs that simultaneously demonstrate strong antioxidant, antibiofilm, neuroprotective, and anti‐inflammatory properties, underscoring their novelty as next‐generation nanomedicines.
Laouini et al. (Mon,) studied this question.